NEW YORK, Feb. 11, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Cnova N.V. securities (NASDAQ:CNV) in connection with Cnova’s initial public offering on or about November 19, 2014 (the “IPO”) and/or from November 19, 2014 through December 18, 2015, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Cnova investors under the federal securities laws.
To join the Cnova class action, go to the firm’s website at http://rosenlegal.com/cases-807.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued materially false and misleading statements to investors and/or failed to disclose that: (1) Cnova overstated net sales; (2) Cnova failed to properly write-off the value of certain returned items; (3) there was a material discrepancy in accounts receivable related to the damaged/returned items; (4) Cnova’s EBIT was overstated; (5) Cnova lacked adequate internal controls; and (6) as a result, defendants’ statements about Cnova’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 21, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-807.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
OpenAI Explores Massive Funding Round at $750 Billion Valuation
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 



